Table 1.
Patient characteristics.
| Included (N = 103) | Excluded (N = 146) | p * | |
|---|---|---|---|
| Age | 46 +/− 11 | 49 +/− 11 | 0.004 |
| Race | 0.54 | ||
| White | 76 (74%) | 115 (79%) | |
| Black or African American | 15 (15%) | 17 (12%) | |
| Asian | 8 (8%) | 8 (5%) | |
| American Indian or Alaska Native | 0 (0%) | 3 (2%) | |
| Others | 3 (3%) | 3 (2%) | |
| Subtype | 0.12 | ||
| HR+ | 62 (60%) | 72 (49%) | |
| HR- | 41 (40%) | 73 (50%) | |
| Treatment | 0.89 | ||
| Paclitaxel | 75 (73%) | 105 (72%) | |
| Paclitaxel + Pembrolizumab | 28 (27%) | 41 (28%) | |
| Menopausal Status | 0.26 | ||
| Premenopausal | 58 (56%) | 68 (47%) | |
| Postmenopausal | 26 (25%) | 49 (34%) | |
| Perimenopausal | 7 (7%) | 6 (4%) | |
| Others | 12 (12%) | 23 (16%) |
* Assessed by Student’s t-test for age and Fisher’s test for categorical variables.